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Abstract
Introduction: Adaptive designs offer a flexible approach, allowing changes to a trial based on examinations of the
data as it progresses. Adaptive clinical trials are becoming a popular choice, as the prudent use of finite research
budgets and accurate decision-making are priorities for healthcare providers around the world. The methods of
health economics, which aim to maximise the health gained for money spent, could be incorporated into the design
and analysis of adaptive clinical trials to make themmore efficient. We aimed to understand the perspectives of
stakeholders in health technology assessments to inform recommendations for the use of health economics in
adaptive clinical trials.
Methods: A qualitative study explored the attitudes of key stakeholders—including researchers, decision-makers and
members of the public—towards the use of health economics in the design and analysis of adaptive clinical trials.
Data were collected using interviews and focus groups (29 participants). A framework analysis was used to identify
themes in the transcripts.
Results: It was considered that answering the clinical research question should be the priority in a clinical trial,
notwithstanding the importance of cost-effectiveness for decision-making. Concerns raised by participants included
handling the volatile nature of cost data at interim analyses; implementing this approach in global trials; resourcing
adaptive trials which are designed and adapted based on health economic outcomes; and training stakeholders in
these methods so that they can be implemented and appropriately interpreted.
Conclusion: The use of health economics in the design and analysis of adaptive clinical trials has the potential to
increase the efficiency of health technology assessments worldwide. Recommendations are made concerning the
development of methods allowing the use of health economics in adaptive clinical trials, and suggestions are given to
facilitate their implementation in practice.
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Introduction
Decision-makers around the world are faced with limited
budgets for funding health research, such as new clini-
cal trials, and funding health technologies, such as new
drugs [1–3]. Resources spent on funding new research
may otherwise be spent directly on patient care, and so
it is desirable to consider the cost-effective use of lim-
ited resources. Themethods of health economics facilitate
resource allocation decisions by evaluating the maximum
health gained for the resources spent [4].
Cost-effectiveness plays an important role at two points
in the health technology assessment (HTA) process: to
determine whether it is cost-effective to fund a new
health technology and whether it is cost-effective to fund
a piece of research. For the first of these questions,
cost-effectiveness analysis compares the costs and ben-
efits (often measured using quality-adjusted life years
(QALYs)) of competing health technologies to identify
which represent value for money [4]. For the second
type of evaluation, value of information analysis (VOIA)
assesses whether it is worthwhile collecting further infor-
mation, such as performing further clinical trials, to
reduce decision uncertainty [5, 6]. Amongst other inputs,
a reliable health economic analysis requires an accurate
estimate of the treatment effect and associated confidence
interval, often provided by a clinical trial.
Adaptive designs are one innovative approach to con-
ducting a clinical trial. Unlike a traditional fixed sample
size design, data are examined as the trial progresses to
informmodifications to the trial. This can potentially save
time and resources, as well as prevent patients from being
needlessly randomised [7–9]. The number of trials using
adaptive methods has increased from 11 per 10,000 reg-
istered trials between 2001 and 2005 to 38 per 10,000
registered trials between 2012 and 2013 [10].
Adaptive designs and their implementation are com-
monly based on demonstrating clinical effectiveness.
Despite its importance, cost-effectiveness is often a sec-
ondary consideration [11]. It is currently unclear what
impact the use of an adaptive design has on a health eco-
nomic analysis. Additionally, opportunities are potentially
being missed to incorporate health economics into the
design and analysis of adaptive clinical trials. The objec-
tive of this paper is to report the views of stakeholders on
the use of health economics in adaptive clinical trials.
Methods
We adopted a pragmatic approach to understanding issues
around the use of health economics in adaptive designs
[12]. An initial thematic framework was developed, based
on the research aims, literature and discussions with
our public advisory group (a group of members of the
public advising on the research). Initial themes identi-
fied included the following: Pre-specification of Health
Economic Analysis; Private Sector Attitude; Aims of a
Clinical Trial and Advantages and Limitations of Adap-
tive Designs. Once data collection was under way, we
amended the framework based on inferences about par-
ticipant perspectives with no obvious place in the initial
framework. The final framework in Table 1 condensed the
themes into three main headings reflecting the key areas
of interest: ethical, methodological and practical issues.
We used a purposive sample to identify the views of a
range of key stakeholders in the HTA process. Members
of the public were recruited regardless of their experi-
ences as a patient, a user of the National Health Ser-
vice (NHS) or a participant in clinical trials. We also
approached researchers and decision-makers involved
in HTA, especially those who might use the proposed
methods.
Members of the public were first contacted through a
public involvement co-ordinator at a clinical research unit
at a local hospital, a departmental public involvement lead
and the public advisory panel supporting the research
project. After the initial data collection, to extend the
reach beyondmembers of the public with research experi-
ence, a message was posted to an online discussion forum
(Sheffield Forum). Researchers and decision-makers were
identified by contacting researchers known to be working
in relevant areas such as prominent health economists,
statisticians and clinicians.
Semi-structured interviews and focus groups were
used to collect data. Data collection with members
of the public was conducted face to face at the Uni-
versity of Sheffield where possible; telephone inter-
views were available to avoid excluding members of
the public who were unable to travel. Interviews were
the preferred approach for researchers and decision-
makers, to reduce the burden on participants, as previous
related research reported difficulties in engaging health
economists [13].
Separate study documentation and topic guides were
produced for the public and researcher groups reflect-
ing the technical language and information provided to
the respective participants. The researcher topic guide
was piloted with a colleague. We implemented recom-
mendations from the project’s public advisory group
on how to modify the topic guide for members of
the public.
Prior to data collection, all participants were sent a short
video introducing the key concepts of adaptive designs
and health economic analysis in plain English to allow full
participation in the study [14]. This video was created with
the support of the public advisory group so as not include
any of LF’s preconceived ideas which might influence the
subsequent responses of the participant.
All interviews and focus groups were conducted by LF
and lasted between 30 to 60 mins and 60 to 90 mins
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Table 1 Final thematic framework applied to the data collected from interview and focus groups HTA; health technology assessment
Theme Subtheme Description Example
Methodological Development Important statistical issues to consider when develop-
ing the use of adaptive designs and health economics
in HTA
How to handle bias in the analysis of group sequen-
tial trials
Advantages and disadvantages of using adaptive
designs and health economics together in clinical tri-
als
Issues with cost data that need to be considered
when developing the methods
Current use How are adaptive designs, economic evaluations and
value of information analysis methods currently used
in practice and what are their advantages and disad-
vantages?
Use of value of information analysismethods is limited
in practice because it is often perceived as compli-
cated
Experience and
knowledge
What experience and knowledge do the participants
have of these methods and where has this come
from?
Members of the public may rely on the media for
information about healthcare decision-making
Ethical Planning Ethical issues that should be considered when plan-
ning trials (before they begin) using adaptive designs
and health economics
The motivations of patients for being involved in trials
can differ, and so using cost-effectiveness as part of a
trial may or may not influence whether people want
to take part
The aims of a clinical trial from all stakeholder perspec-
tives (when talking at a societal/personal level rather
than statistical)
The context where these methods are appropriate
from an ethical point of view, e.g. end of life
Historical case studies have influenced changes in
policy and how we run clinical trials, and methods
need to reflect this
Implementation
and conduct
Ethical issues that should be considered when con-
ducting or implementing trials using adaptive designs
and health economics in the real world (during the
trial)
The methods could allow the assumption of
equipoise to be compromised at interim analyses
Protecting participants in trials if the trial stops
How the DMEC would be composed in these trials
Documenting
and reporting
Ethical issues that should be considered when writing
documentation for trials using adaptive designs and
health economics (not just reporting after the trial has
ended)
Informed consent is key to any trial, and provid-
ing participants and potential participants with the
appropriate level of information is important
Practical Planning Practical issues to consider when planning a
trial/before conducting a trial with an adaptive design
and health economic analysis
Who will need training and what sort of training
would be appropriate?
The level of complexity in the methods needs to be
acceptable to funding panels reviewing grant appli-
cations and the agencies reviewing the evidence
The role of public involvement
Context where you could implement these methods
from a practical point of view
Implementation
and conduct
Practical issues to consider when conducting or
implementing a trial with an adaptive design and
health economic analysis
How should interim decision-making be handled and
what influence should competing factors have?
Issues with cost data that might impact the practical
application of this work
Development of guidance documents for researchers
implementing these methods
Documenting
and reporting
Practical issues to consider when reporting and writ-
ing documentation for a trial with an adaptive design
and health economic analysis (not just reporting
when trial has ended)
Documentation required throughout the trial process
such as what to include in a protocol and analysis
plans (pre-specification)
Additional reporting requirements when publishing
this research
Reporting requirements for interim analyses
The framework was informed by existing literature [35, 44–57], discussions with the public advisory group and early data collected
respectively. The interviews and focus groups were audio
recorded. The interviews were anonymised and tran-
scribed. Demographic data were collected using an online
Google Form.
Based on the literature [15–20], advice from the
public advisory group, and keeping time constraints
in mind, a target of a maximum of 20 researchers
and 20 members of the public was set. Focus groups
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were planned to have a maximum of seven partici-
pants. At each stage the demographics of the sam-
ple were reviewed and subsequent participants selected
to give a balanced and representative sample where
possible, similar to the approach recommended by
Francis et al. (2010) [21].
Transcriptions were imported into NVivo (QSR Inter-
national v11,Melbourne, Australia). A framework analysis
approach was adopted [22] and followed the recom-
mended stages [23]:
1. Familiarisation with the data using the transcripts
and any notes made during data collection
2. Coding the transcripts line by line and assigning a
code from the a priori thematic framework or a new
code
3. Updating the thematic framework with any
new codes emerging from the data
4. Indexing transcripts using the categories and codes
from the thematic framework
5. Charting data into a matrix summarising the data
from each participant relevant to each of the
categories from the thematic framework
6. Interpreting the results in the context of the research
aims.
This included discussion of the findings with the public
advisory panel. A table of recommendations was also sent
to all study participants, who were given the opportunity
to comment and suggest changes.
Ethics approval was granted by the University of
Sheffield, School of Health and Related Research Ethics
Committee (ref 009699). All participants were issued an
information sheet and were required to sign a consent
form or give verbal consent before data collection. The
COREQ (Consolidated criteria for reporting qualitative
research) checklist has been used in the reporting of this
study [24] (see Additional file 1).
Results
Description of participants
In total, 29 participants took part in the study between
October 2017 andMarch 2018. At this point it was felt that
few new themes were emerging and a range of participants
had been included. We conducted 18 one-to-one inter-
views and two focus groups. There were no repeat inter-
views. The participant characteristics are summarised in
Table 2. One researcher did not complete the demo-
graphic survey. There were 213 female researchers and
8
15
female members of the public. Researchers predominantly
came from statistical or health economic areas of exper-
tise from both the private and public sectors. Two of the
13 researchers were based in the USA. Ten of 15 members
of the public had participated in research through public
involvement groups and 615 had participated in a clinical
trial.
The health economists interviewed had limited expe-
rience with adaptive designs and reported that they are
frequently not consulted in the design of clinical trials.
Researcher participants suggested that health economists
and statisticians frequently work independently, with their
key point of contact often being the trial chief investiga-
tor. However, study participants did not feel this negatively
impacted their work.
The knowledge and experience of members of the pub-
lic who took part in the study came predominately from
three main sources: the media, involvement in research
as public advisors or participation in a clinical trial. Par-
ticipants acknowledged that the media was likely to give
biased views on healthcare decision-making for the gen-
eral public and there was perhaps a lack of trustworthy
resources available.
Current practice
Increasing the prominence of cost-effectiveness; improv-
ing the quality of health economic analyses; and
preventing adaptive designs stopping before there is
sufficient evidence for an accurate health economic
analysis were suggested by study participants as some
of the advantages of using health economics in adap-
tive designs. A study participant suggested that while
formal VOIA calculations are rare, informal ‘rules
of thumb’ based on the same ideas are common-
place. Developing decision rules for cost-effectiveness
of the research similar to the rule for clinical effec-
tiveness (p<0.05) and cost-effectiveness of the inter-
vention (willingness-to-pay thresholds) would help the
practical interpretation and implementation of this
approach.
Few participants had seen the use of health economics
in the design and analysis of adaptive clinical trials in
practice. It was felt that further work is needed to extend
the existing theory to the real-world context, and con-
cerns were raised that combining these two complex
methods might be deemed too challenging and hin-
der their uptake. It was also suggested that improve-
ments to the methods of VOIA were required to provide
accepted standards such as the time horizon over which
value of information is calculated. The use of adaptive
designs and VOIA in trial design and research prioritisa-
tion would need to be more commonplace before adding
further complexity and combining the two approaches
in a trial.
. . .putting both together is going to be doubly compli-
cated and time consuming and costly and so on . . . P35
Health economist
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Table 2 Demographics of participants who took part in interviews or focus groups. One researcher did not complete the
demographics questionnaire
Question Response Public (n = 15) Researcher (n = 13)
Gender Female 8 2
Male 7 11
Ethnicity (free text) White, European 1 0
White 3 3
White British 8 7
English 1 0
Asian 1 1
British 1 1
Caucasian 0 1
Age (years) 30 or younger 1 1
31–35 0 3
36–40 5 2
41–45 0 2
46–50 1 2
Older than 50 8 3
Highest academic qualification Doctorate 1 8
Post-graduate degree (Masters) 2 5
Registered nurse & registered midwife 1 0
Undergraduate degree 6 0
Undergraduate degree, teaching certificate 1 0
General Certificate of Secondary Education 1 0
NA 3 0
Have you ever participated in a clinical trial? No 9 -
Yes 6 -
Have you ever been a member of a public involvement group? No 5 -
Yes 10 -
Experience in clinical trials research (years) 11–15 years - 5
16–20 years - 1
5–10 years - 1
Less than 5 years - 2
More than 20 years - 3
NA - 1
Current employment sector Private - 6
Public - 7
Location United Kingdom - 11
United States of America - 2
Area of expertise (can choose multiple) Clinician - 1
Health economics - 8
Health services research - 1
Value of information analysis - 2
Adaptive designs - 3
Clinical trial management - 1
Statistics - 5
Ethical considerations
Participants in the qualitative study agreed that clinical
effectiveness is themain aim of a clinical trial, whether it is
adaptive or a fixed sample size design. Both researcher and
public participants could appreciate the importance of
demonstrating cost-effectiveness in a trial; however, they
felt it was still important to answer the clinical question
first.
It feels to me like it might be unfortunate to move into
a world where, where clinical research, in general per se,
was shaped too much, designed too much with economic
considerations.. . . P19 Member of the public
On the other hand, some participants argued that
cost-effectiveness decisions provide unseen benefits in
healthcare. For example, if a trial stopped early on
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cost-effectiveness grounds, this would allow resources to
be spent elsewhere in a more cost-effective way, confer-
ring benefits to participants outside of the clinical trial.
One researcher suggested that incorporating health eco-
nomics into the adaptive design changes the focus of the
trial from the individual to a population level. However,
others felt this might be deemed unacceptable to some
stakeholders in the HTA process.
A number of the participants agreed that a health
economist should be included on a data monitoring and
ethics committee (DMEC) if health economics is used as
part of the design and analysis of an adaptive trial. On
the other hand, one researcher argued that funding deci-
sions should be made by the funder, and it would not be
appropriate to delegate this responsibility to the DMEC.
. . . the DMEC have a very specific role looking at safety
[. . . ]. But once you get into value of information that’s
the funder’s decision and I don’t think the funder should
delegate that to the DMEC. P1 Funding panel member
Methodological considerations
A number of participants were concerned about how
the volatile nature of cost data would be handled
if interim adaptations were made based on cost-
effectiveness. This adds complexity when deciding
whether to modify (or even stop) a trial on a given
day when an interim analysis takes place, as this may
be the wrong decision if, for example a drug price
decreases.
There’s still this question of whether it is cost economic
now as per tomorrow, so you might miss an opportunity.
P6 Statistician
Study participants also highlighted that global multi-
centre trials may encounter difficulties when using cost-
effectiveness to inform interim adaptations. An interim
analysis in one centre might demonstrate sufficient evi-
dence to stop the trial early based on the cost-effectiveness
rules in their jurisdiction, but this might not be reflected
in the other centres around the world. Additionally, the
extent to which adaptive trials incorporate health eco-
nomics in the private sector might depend on whether
the focus is on the US market or other countries where
cost-effectiveness plays amore prominent role, such as the
UK.
It was unappealing to many participants, that an adap-
tive design could stop early based on the cost-effectiveness
of the intervention or the research itself. Alternative uses
for the interim data suggested by participants included:
1. A hierarchy of stopping rules, where the clinical
outcome is the first consideration in the adaptive
decision-making and then, dependent on this result,
cost-effectiveness may also be used to inform
modifications to the trial.
2. The trial could be modified based on health
economic grounds rather than the more extreme
case of stopping a trial.
Practical considerations
Study participants felt that successfully implementing
this approach would require sufficient resourcing, care-
ful planning and also building a study team of researchers
and clinicians who have sufficient training and are sup-
portive of the approach. Adding the health economic layer
to adaptive clinical trials raised a resourcing problem for
many participants, as more time and resources will be
required before a project has been funded. In the private
sector, this type of impact was thought to vary depending
on the size of the company.
Funding panels and HTA committees are composed of
non-experts who will require sufficient training in the
methods to allow them to assess their appropriateness
in answering the research question and to interpret and
assess the quality of the evidence. Study participants high-
lighted the value of developing software to help make
methodology accessible and increase its use. Case stud-
ies were suggested as a way of demonstrating the value
of using health economics in adaptive clinical trials. This
could increase the understanding of the methods and
appease the concerns of many participants regarding the
complexity of this approach. The methodology would
need to be presented in an accessible way for non-experts.
. . . the crucial thing is that the analysis has to be
very understandable because [. . . ] in practice it will be
unhelpful if a value of information analysis was updated
and appeared to everyone involved in the trial to be a
black box analysis. P1 Funding panel member
It will be increasingly important for the health economic
analyses to be pre-specified if used to inform adaptive
decision-making during a trial. There would need to be
a greater level of scrutiny of the health economic analy-
ses. However, concerns were also raised by participants
about the potential challenge of pre-specifying everything
for a health economic analysis prior to any trial results.
Participants working in industry were concerned about
the impact of early examinations of the data on cost-
effectiveness grounds and the requirements to publicly
report all analyses.
. . . it’s sort of . . . you’ve got chicken and egg here. [. . . ] Your
model is developed as you look at the data but I think it
would be quite difficult to do that because, yeah they sort
of evolve alongside each other P39 Health economist
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Discussion
Members of the public, researchers and decision-makers
identified ethical, methodological and practical issues
associated with the use of health economics in adaptive
clinical trials. Recommendations and proposed actions
were drawn from the themes identified in the data, reflect-
ing the differing views of stakeholders in the HTA process
and experiences of the research team and public advisory
group. Recommendations are discussed under the three
key themes—ethical, methodological and practical—and
are summarised in Table 3.
Ethical considerations
Currently the use of health economics in the design and
analysis of adaptive and non-adaptive clinical trials is
largely secondary to clinical outcomes [11]. Study partici-
pants felt that for health economics to play a greater role
there needs to be a shift of emphasis from the ethical
perspective of beneficence—the duty to allocate resources
to benefit the individual [25]—to the broader perspec-
tive of distributive justice: allocating resources to benefit
the whole population [26, 27]. Changing the status quo
requires the public and policy makers to find compelling
ethical arguments showing that cost-effectiveness deci-
sions provide an unseen benefit [28]. We recommend
developing unbiased and simple materials on adaptive
designs and health economics. Public advisors could be
used to develop materials and consent forms that explain
the methods of adaptive designs and health economics in
sufficient detail for potential trial participants to make an
informed decision to participate, as well as highlighting
the broader implications of taking part in the research.
The acceptability of the role of cost-effectiveness to
stakeholders is crucial when considering the direction of
methods development. It is fruitless to develop statisti-
cal methods that incorporate health economics into an
adaptive design if this is never implemented in practice
due to concerns over the role of cost-effectiveness. For
example, patients may be unwilling to be randomised,
as they do not agree with decision-making centred on
cost-effectiveness. Based on discussions with the study
participants and the public advisory group, we recom-
mend exploring alternative approaches, including the
following:
• Interim analyses used to check that all health
economic data are being collected as required
• Interim data used to update the health economic
model
• A hierarchy of interim decision rules where the
health economic decisions are dependent on the
outcome of the clinical effectiveness analysis
• Health economics decision rules that are only
considered at later interim analyses, giving the
advantage of more mature data and also more weight
to clinical outcomes at the start of the trial
• Health economics used to make less extreme
modifications such as increasing the sample size
based on an expected value of sample information
calculation.
The choice of approach could be made in collaboration
with a public advisor so that the identified approach is
acceptable to patients.
Methodological considerations
The advantages of using health economics in adaptive
designs include saving resources and preventing patients
from being needlessly randomised [11, 29, 30]. Such
an approach will formalise the informal rules of thumb
described by a study participant as commonly used by
decision-makers and funding panels, so that they can be
applied in an objective and consistent manner. We sug-
gest that developing decision rules for cost-effectiveness
of the research, similar to the rule for clinical effective-
ness (p values) and cost-effectiveness of the intervention
(willingness-to-pay thresholds), would help the practi-
cal interpretation and implementation of this approach.
Public advisors could be used to ensure these rules are
appropriate and reflect the views of patients and the
public.
It will also be important to consider the limitations of
both methodologies, including the potential for adaptive
designs to introduce bias in the estimation of point esti-
mates and confidence intervals and maintaining appropri-
ate levels of blinding during interim analyses so as not to
influence the conduct of the trial [31, 32].
The methods of adaptive designs and value of infor-
mation analysis (VOIA) are not commonplace in HTA
[10, 33, 34]. It will be vital to address the limitations of
these methods to successfully implement them together
in clinical trials. As identified by the study participants,
these methods could be seen as more complex, poten-
tially acting as a barrier to their use in practice. Work
in the field of adaptive designs to promote their use and
understanding amongst the health research community
includes:
• The Adaptive Designs Working Group, part of the
Medical Research Council (MRC) Hubs for Trials
Methodology Research, which aims to increase
implementation of adaptive designs through tutorial
papers in mainstream medical journals (see, e.g. [32]),
development of software and presentations and
lectures
• The Adaptive CONSORT Extension (ACE) project,
which aims to enhance transparency, credibility,
reproducibility and replicability of adaptive trials by
developing a consensus-driven extension to the
Flight et al. Trials          (2020) 21:252 Page 8 of 12
Table 3 Summary of key recommendations and proposed actions from the interviews and focus groups with members of the public,
researchers and decision-makers
Issue Recommendation Action
Clinical effectiveness is the main
focus when thinking about the aims
of a clinical trial
The importance of clinical effectiveness should
be reflected in the development of methods for
using health economics in adaptive trials. Possible
approaches include:
• Using early examinations of the trial to check
that all health economic data are being
collected as required
• Using early trial data to update the health
economic model
• Using a hierarchy of interim decision rules
where any decisions made based on
cost-effectiveness depend on decisions
made about clinical outcomes
• Only considering health economic outcomes
at later examinations of the data
• Using health economic data to make
modifications to the trial such as increasing
the sample size but not major changes such
as stopping the trial early
Explore how existing methods for the use of health
economic-based stopping rules would work in the real-
world setting, by applying the methods to a diverse
range of case studies
Study participants appreciate the
importance of cost-effectiveness to
decision-makers, but they consider
this to be secondary to clinical
effectiveness
There needs to be a change in the mentality of
the research community towards the role of health
economics and cost-effectiveness in healthcare
decision-making
Development of materials to educate on the
importance and ethical motivations for thinking about
cost-effectiveness. This could be written with members
of the public and developed into workshops, online
materials and leaflets
Stakeholders may not be familiar
with the methods of adaptive
designs or value of information
analysis and their potential
advantages and limitations
Develop software and tutorial style case studies for
researchers to help them understand the methods
and allow them to interpret the results of trials
using this approach or use these methods in their
own research
Development of plain English summaries and case
studies highlighting the impact of the methods on
patients and the public
A Practical Adaptive and Novel Designs and Analysis
(PANDA) Toolkit is under development that aims to
provide researchers with training materials on adaptive
design clinical trials [58]. This could include materials
aimed at members of the public
Organise workshops (such as at conferences) for
researchers, highlighting the potential for the methods
to be used together and issues to consider
If health economics is to inform
decisions made using early
examinations of data, there may be
a need for this specialist knowledge
on trial committees
Include health economists on DMECs where health
economics is used as part of the design and
analysis of adaptive trials
Existing resources that help research teams identify
DMEC statisticians, such as StatLink [40], could be
extended to identify health economists. All DMEC
members could be paid for their contribution and time
Use mock DMECs to allow members to review the
health economic and clinical data and see where issues
with using the health economic data arise
Using health economics in the
design and analysis of adaptive
trials will require more work
before the trial is funded, when
researchers may not be paid for this
work
Funding bodies should provide alternative
funding options that allow researchers to develop
new designs
Researchers could include time at the start of a
study to fully develop an adaptive trial design that
uses health economics
Researchers should look for methodology grants
to fund the development of designs
Groups representing statisticians and health economists
(such as the MRC Adaptive Designs Working Group and
ISPOR—the Professional Society for Health Economics
and Outcomes Research) should work together to
persuade funders and regulators of the need for
alternative ways to fund adaptive clinical trials and the
benefits this will have to health research andmaximising
limited research budgets
There is currently limited interaction
between health economists and
statisticians working on trials and
more generally between the two
research communities
Encourage statisticians and health economists to
work together and increase communication to
facilitate the implementation of health economics
in adaptive trials by sharing expertise
Locally, health economists and statisticians working on
the same clinical trial should have regular meetings
throughout the study. Nationally, there could be joint
events between groups such as the NIHR Statistics
Group and the Health Economic Study Group to discuss
common issues and encourage training in statistics for
health economists and health economics for statisticians
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Table 3 Summary of key recommendations and proposed actions from the interviews and focus groups with members of the public,
researchers and decision-makers (Continued)
Issue Recommendation Action
If health economics is to be used in
adaptive clinical trials, the methods
need to be outlined in advance so
the results of the trial are still valid
and robust
Before the trial begins, researchers should outline
how health economics is going to be used in the
trial and how the early examinations of the data will
be used to calculate cost-effectiveness and inform
decision-making
Extend current work developing guidance for health
economic analysis plans to think about specific issues
that might arise in adaptive clinical trials [42]. This will
likely require health economists to have some
experience of working on an adaptive trial
Calculating the costs of conducting
an adaptive clinical trial can be
complicated. For example, one
must provide justifications of costs
and cost projections in a grant
application
It is important to understand the costs of
conducting an adaptive trial such as the costs of
finding patients, training staff and analysing data so
that one can compare adaptive and non-adaptive
trial designs and inform stopping rules based on
health economics
Develop a standardised approach for calculating the
costs of an adaptive clinical trial, illustrated using a case
study
CONSORT (Consolidated Standards of Reporting
Trials) statement specific to adaptive designs [35].
Measures for increasing the use of value of information
analyses include:
• The Professional Society for Health Economics and
Outcomes Research (ISPOR) Value of Information
Analysis for Research Decisions task force, which
aims to develop good practice guidance for using
methods of value of information analysis to inform
both technology reimbursement decisions and
research prioritisation decisions [36]
• Collaborative Network for Value of Information
(ConVOI) group, an international network working
to improve the calculation, adoption and application
of value of information methods in clinical and public
health research [37, 38].
We recommend the use of similar initiatives to promote
the use of health economics in the design and analysis of
adaptive clinical trials.
Practical considerations
If the use of health economics becomes common in the
analysis of adaptive designs, then guidance on the com-
position of DMECs [39] should be updated, and lists
which help identify DMEC members—such as StatLink
[40]—could be extended to include health economists.
Such an approach will have cost consequences for clin-
ical trials with the involvement of health economists
throughout. There will be a requirement to conduct more
analyses such as model conceptualisation prior to the trial
being funded [13]. However, the development of a health
economic model and cost-effectiveness analyses based on
systematically reviewed current evidence is an essential
step prior to undertaking any trial regardless of its design
[41]. In the public sector, where there are few resources to
bridge grant funding, researchers would need to include
the costs of trial design within grant applications. Groups
representing statisticians and health economists will need
to persuade funders and regulators of alternative ways
to fund adaptive clinical trials and value of information
analyses.
If health economics is to be successfully implemented
as part of an adaptive clinical trial, we recommend that
trial sponsors need to ensure integrated working between
health economists and statisticians throughout the trial
process. More generally, across the research community
links between statisticians and health economists could
be encouraged through networking events and joint work-
shops to identify common ground and explore ways of
working together more efficiently.
Pre-specification of health economic analyses will be
crucial in maintaining the validity and integrity of adap-
tive designs that use health economics, with analysis plans
including a description of the monitoring and adapta-
tion plan, as well as pre-specification of methods used
at interim analyses [29, 42]. The timing of interim anal-
yses must be realistic given their complexity, and their
blinding must be carefully considered. Cross-disciplinary
training materials will be required, supplemented by case
studies on the use of health economics in sequential tri-
als [43], to raise awareness and advance methodological
development by highlighting practical problems with their
application.
Strengths and limitations
This is the first qualitative study to explore the ethi-
cal, methodological and practical issues of using health
economics in the design and analysis of adaptive clini-
cal trials. Participants came from different backgrounds
and with experiences across the healthcare decision-
making process. This study included a number of health
economists, a group previously found to be hard to reach
in adaptive designs research [13]. Members of the pub-
lic were an important stakeholder group in this research,
as the ultimate beneficiaries of clinical trials and health-
care decision-making that uses an adaptive design and
health economic analysis. Additionally, members of the
public are all potential participants in trials that use these
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methods. Failing to reflect their views in the design and
analysis of clinical trials could, for example, make it diffi-
cult to recruit to trials that use an unpopular design based
on cost-effectiveness.
Few female researchers took part in the study; however,
it is not felt that the gender of the participants is likely
to influence their responses. Instead, participants’ knowl-
edge and experiences are more likely to inform their com-
ments. Further work could consider a larger sample size
and a broader range of experience of participants, such
as programme managers at funders such as the National
Institute for Health Research.
A public advisory group played an intrinsic part in the
design and analysis of the qualitative study. The group
were given training in adaptive designs and health eco-
nomics by LF. They provided feedback on the informa-
tion sheet, consent form and topic guide for members
of the public to ensure the questions and proposed plan
were suitable. The group developed the script for the
short video sent to all study participants. After analy-
sis was complete, the group met again to discuss the
results and check the interpretation of findings. Where
appropriate, their interpretation has been embedded in
the paper.
A limitation of the research is that the members of the
public and non-expert researchers and decision-makers
were given a top-level understanding of the topics of value
of information; thus, their responses are considering a
broad view of cost-effectiveness considerations in clinical
trials. However, the views of participants are still impor-
tant in understanding the priorities of the stakeholder
groups around the role of cost-effectiveness in adaptive
clinical trials. Further work could consider amore detailed
explanation of the methods of value of information analy-
sis, providing scenarios of potential roles for the methods
in adaptive clinical trials and using these to explore the
views of stakeholders with a deeper understanding of the
method.
Conclusion
The use of health economics in the design and analysis
of adaptive clinical trials has the potential to increase the
efficiency of health technology assessments worldwide.
However, careful consideration is needed to ensure that
the statistical methods reflect the importance of clinical
effectiveness to stakeholders and that adequate training
and resources are provided to facilitate the implementa-
tion of this approach.
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